Feldman, Darren R.

Publications

Sort by

Co-Author Network

selected publications

Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 15
The experience of hearing loss in adult survivors of childhood and young adult cancer: A qualitative study. Cancer. 2020 Academic Article GET IT
Times cited: 11
Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 20
Testicular cancer. Nature reviews. Disease primers. 2018 Review GET IT
Times cited: 143
Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. Urology. 2018 Academic Article GET IT
Times cited: 7
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 88
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. European journal of cancer. 2018 Academic Article GET IT
Times cited: 285
Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors. Journal of the National Comprehensive Cancer Network : JNCCN. 2018 Academic Article GET IT
Times cited: 25
Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. Clinical genitourinary cancer. 2018 Academic Article GET IT
Times cited: 23
Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. Urology. 2018 Academic Article GET IT
Times cited: 11
Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 14
Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. 2017 GET IT
Times cited: 21
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. Urologic oncology. 2017 Academic Article GET IT
Times cited: 21
Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. European urology focus. 2017 Academic Article GET IT
Times cited: 28
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. European urology focus. 2017 Academic Article GET IT
Times cited: 37
Oncologist use and perception of large panel next-generation tumor sequencing. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 32
Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 53
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. 2017 GET IT
Times cited: 23
Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 66
Cisplatin Therapy Does Not Worsen Renal Function in Severe Antenatal Bartter Syndrome. 2017 GET IT
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature medicine. 2017 Academic Article GET IT
Times cited: 2338
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. Clinical genitourinary cancer. 2017 Academic Article GET IT
Times cited: 35
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urologic oncology. 2017 Academic Article GET IT
Times cited: 21
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 80
Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 63
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 588
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 67
Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. Urology. 2016 Academic Article GET IT
Times cited: 12
Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. The Journal of urology. 2016 Academic Article GET IT
Times cited: 9
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 141
Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. European urology focus. 2016 Academic Article GET IT
Times cited: 28
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. European urology focus. 2016 Academic Article GET IT
Times cited: 38
The Management of Advanced Germ Cell Tumors in 2016: The Memorial Sloan Kettering Approach. Oncology (Williston Park, N.Y.). 2016 Review GET IT
Times cited: 10
Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 200
Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis. European urology. 2016 Article GET IT
Times cited: 32
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. The oncologist. 2016 Academic Article GET IT
Times cited: 83
Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. Urology. 2016 Academic Article GET IT
Times cited: 3
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 35
Are Some Cases of Somatic Type Malignancy Potentially Avoidable?. The Journal of urology. 2016 Editorial Article GET IT
Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. PloS one. 2015 Academic Article GET IT
Times cited: 16
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 70
Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer. The Journal of urology. 2015 Academic Article GET IT
Times cited: 16
Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Review GET IT
Times cited: 68
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 7
Late Relapse of Testicular Germ Cell Tumors. The Urologic clinics of North America. 2015 Review GET IT
Times cited: 24
Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Review GET IT
Times cited: 10
Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 8
Update in germ cell tumours. Current opinion in oncology. 2015 Review GET IT
Times cited: 13
Salvage high-dose chemotherapy for germ cell tumors. Urologic oncology. 2015 Information Resource GET IT
Times cited: 10
Interrogation of a context-specific transcription factor network identifies novel regulators of pluripotency. Stem cells (Dayton, Ohio). 2015 Academic Article GET IT
Times cited: 21
Editorial comment. Urology. 2014 Editorial Article GET IT
Times cited: 2
Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. The Journal of urology. 2014 Academic Article GET IT
Times cited: 19
Microwave ablation (MWA) for the treatment of a solitary, chemorefractory testicular cancer liver metastasis. 2014 GET IT
Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis. Clinical genitourinary cancer. 2014 Academic Article GET IT
Times cited: 30
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 71
The role of high-dose chemotherapy in the management of germ cell tumors. Current opinion in oncology. 2014 Review GET IT
Times cited: 2
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. Journal of the National Cancer Institute. 2014 Review GET IT
Times cited: 103
Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. The Journal of urology. 2014 Academic Article GET IT
Times cited: 41
Beyond stage I germ cell tumors: current status regarding treatment and long-term toxicities. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2014 Review GET IT
Times cited: 4
Fertility preservation strategies for male patients with cancer. Nature reviews. Urology. 2013 Review GET IT
Times cited: 30
Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clinical genitourinary cancer. 2013 Academic Article GET IT
Times cited: 52
Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer. 2013 Academic Article GET IT
Times cited: 22
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Investigational new drugs. 2013 Academic Article GET IT
Times cited: 38
Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death. Urologic oncology. 2013 Academic Article GET IT
Times cited: 15
Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors. The International journal of developmental biology. 2013 Review GET IT
Times cited: 46
The conundrum of clinical trials in adult germ-cell tumours. The Lancet. Oncology. 2013 Academic Article GET IT
Times cited: 3
Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. PloS one. 2012 Academic Article GET IT
Times cited: 78
Rare de novo germline copy-number variation in testicular cancer. American journal of human genetics. 2012 Academic Article GET IT
Times cited: 17
Late cardiovascular toxicity following chemotherapy for germ cell tumors. Journal of the National Comprehensive Cancer Network : JNCCN. 2012 Review GET IT
Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site. Urology. 2012 Academic Article GET IT
Times cited: 6
Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012 Academic Article GET IT
Times cited: 23
Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology. 2012 Academic Article GET IT
Times cited: 20
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. European journal of cancer. 2011 Review GET IT
Times cited: 38
Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. Urology. 2011 Academic Article GET IT
Times cited: 17
Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. American journal of clinical oncology. 2011 Academic Article GET IT
Times cited: 73
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011 Academic Article GET IT
Times cited: 104
Paclitaxel, ifosfamide and cisplatin (TIP) beyond its original indication for salvage treatment of germ cell tumors. Onkologie. 2011 Editorial Article GET IT
Times cited: 3
High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 344
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer. 2011 Academic Article GET IT
Times cited: 42
High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. Expert review of anticancer therapy. 2011 Review GET IT
Times cited: 15
Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. Journal of Cancer. 2011 Academic Article GET IT
Times cited: 47
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. Hematology/oncology clinics of North America. 2011 Review GET IT
Times cited: 14
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. The oncologist. 2011 Review GET IT
Times cited: 70
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Investigational new drugs. 2011 Review GET IT
Times cited: 38
Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update. Urology. 2011 Academic Article GET IT
Times cited: 11
Contemporary lymph node counts during primary retroperitoneal lymph node dissection. Urology. 2010 Academic Article GET IT
Times cited: 14
Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. Cancer. 2010 Academic Article GET IT
Times cited: 27
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Investigational new drugs. 2010 Academic Article GET IT
Times cited: 80
The approach to the patient with synchronous bilateral germ cell tumors: a lesson in oncologic prioritization. Oncology (Williston Park, N.Y.). 2010 Comment GET IT
Times cited: 4
Testicular cancer survivorship: research strategies and recommendations. Journal of the National Cancer Institute. 2010 Review GET IT
Times cited: 241
Natural immunity to pluripotency antigen OCT4 in humans. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 71
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 197
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 48
Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 69
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Investigational new drugs. 2009 Academic Article GET IT
Times cited: 60
Good-risk-advanced germ cell tumors: historical perspective and current standards of care. World journal of urology. 2009 Information Resource GET IT
Times cited: 10
Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. 2009 GET IT
Times cited: 270
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008 Academic Article GET IT
Times cited: 4
Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. Clinical genitourinary cancer. 2008 Academic Article GET IT
Times cited: 15
Medical treatment of advanced testicular cancer. JAMA. 2008 Review GET IT
Times cited: 270
Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?. Nature clinical practice. Urology. 2007 Comment GET IT
Times cited: 1
Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials. Nature clinical practice. Oncology. 2007 Comment GET IT
Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute. 2007 Letter GET IT
Times cited: 16
Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Investigational new drugs. 2007 Academic Article GET IT
Times cited: 21
Novel targets and therapies for metastatic renal cell carcinoma. Oncology (Williston Park, N.Y.). 2006 Review GET IT
Times cited: 15

more ...

less ...

Background

education and training

M.D., University of Maryland School of Medicine 2001
B.S., Emory University 1997

Contact

full name

Darren R. Feldman

VIVO Weill Cornell Medical College

Darren R. Feldman Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name